VK2735 vs Semaglutide
Comparing Viking Therapeutics' dual GLP-1/GIP agonist VK2735 with Novo Nordisk's GLP-1 agonist semaglutide.
Last updated: February 1, 2026
VK2735
Semaglutide
Overview
VK2735 is Viking Therapeutics’ investigational dual GIP/GLP-1 receptor agonist being developed in both injectable and oral formulations. It targets the same receptor combination as tirzepatide, positioning it as a potential competitor in the dual agonist space. Semaglutide remains the established GLP-1 comparator.
Mechanism Comparison
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| Target Receptors | GIP + GLP-1 | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| Mechanism Class | Same as tirzepatide | GLP-1 analog |
| Developer | Viking Therapeutics | Novo Nordisk |
Dual vs Single Agonism
VK2735 uses the same dual agonist approach as tirzepatide:
- GLP-1: appetite suppression, glucose control
- GIP: enhanced insulin secretion, potential central effects
- Combination may provide superior weight loss
Evidence Comparison
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| Development Phase | Phase 2 | FDA Approved |
| Human Trials | VENTURE program | Extensive |
| Oral Program | Phase 1 | Rybelsus approved |
| Data Maturity | Early | Extensive |
Clinical Trial Data
VK2735 Injectable (Phase 2 - 13 weeks)
| Dose | Weight Loss |
|---|---|
| 2.4mg weekly | ~14.7% |
Context: Short duration, but impressive early results.
VK2735 Oral (Phase 1)
| Observation | Result |
|---|---|
| Weight Loss | ~3.3% (single dose study) |
| Tolerability | Acceptable |
| Oral bioavailability | Demonstrated |
Semaglutide Comparison
| Drug | Trial | Duration | Weight Loss |
|---|---|---|---|
| Semaglutide 2.4mg | STEP 1 | 68 weeks | ~14.9% |
| Oral semaglutide | OASIS 1 | 68 weeks | ~15.1% |
Regulatory Status
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Injectable Phase | Phase 2 | N/A |
| Oral Phase | Phase 1 | Approved (Rybelsus) |
| Expected Timeline | 2026+ | Available now |
Development Strategy
VK2735 Programs
| Formulation | Status | Differentiation |
|---|---|---|
| Injectable | Phase 2 | Dual agonist |
| Oral | Phase 1 | Dual agonist + oral |
Why Oral Dual Agonist Matters
| Factor | Oral VK2735 (potential) | Oral Semaglutide |
|---|---|---|
| Mechanism | GIP + GLP-1 | GLP-1 only |
| Food restrictions | TBD | Yes (fasting) |
| Expected efficacy | Higher (dual) | Proven |
An oral dual agonist would be differentiated from Rybelsus.
Side Effect Profile
| Effect | VK2735 (Early Data) | Semaglutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| GI tolerability | Being characterized | Well-understood |
| Discontinuation | Low in trials | ~7% |
Competitive Positioning
Dual GIP/GLP-1 Landscape
| Compound | Developer | Status | Differentiator |
|---|---|---|---|
| Tirzepatide | Eli Lilly | Approved | First-in-class |
| VK2735 | Viking | Phase 2 | Smaller, faster |
| Orforglipron | Eli Lilly | Phase 3 | Oral (GLP-1 only) |
VK2735 is behind tirzepatide but could be a fast-follower.
Key Differences
| Factor | VK2735 | Semaglutide |
|---|---|---|
| GIP activity | Yes | No |
| Expected efficacy | Higher (dual) | ~15% |
| Approval status | Investigational | Approved |
| Oral program | Dual agonist | GLP-1 only |
| Company size | Small biotech | Large pharma |
Developer Considerations
| Factor | Viking Therapeutics | Novo Nordisk |
|---|---|---|
| Resources | Limited | Extensive |
| Development speed | Fast for size | Well-funded |
| Partnership potential | Likely needed | N/A |
| Manufacturing | Challenge | Scaled |
Summary
- VK2735 is a dual GIP/GLP-1 agonist showing impressive early weight loss (~15% at 13 weeks)
- Semaglutide is the established GLP-1 agonist with proven efficacy and CV benefit
- Dual agonism (same as tirzepatide) likely confers efficacy advantages
- Oral VK2735 program could differentiate from oral semaglutide
- Viking’s small size may require partnership for full development
This comparison is for educational purposes only. VK2735 is investigational. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.